The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.
Immuno-Oncology: Emerging Targets and Combination Therapies
Open accessAbstract
Host immunity recognizes and eliminates most early tumor cells, yet immunological checkpoints, exemplified by CTLA-4, PD-1 and PD-L1, pose a significant obstacle to effective antitumor immune responses. T-lymphocyte co-inhibitory pathways influence intensity, inflammation and duration of antitumor immunity. However, tumors and their immunosuppressive microenvironments exploit them to evade immune destruction. Recent PD-1 checkpoint inhibitors yielded unprecedented efficacies and durable responses across advanced-stage melanoma, showcasing potential to replace conventional radiotherapy regimens. Neverthless, many clinical problems remain in terms of efficacy, patient-to-patient variability and undesirable outcomes and side effects. In this review, we evaluate recent advances in the immuno-oncology field and discuss ways forward. First, we give an overview of current immunotherapy modalities, involving mainy single agents, including inhibitor monoclonal antibodies (mAbs) targeting T-cell checkpoints of PD-1 and CTLA-4. However, neoantigen recognition alone cannot eliminate tumors effectively in vivo given their inherent complex micro-environment, heterogeneous nature and stemness. Then, based mainly upon CTLA-4 and PD-1 checkpoint inhibitors as a ‘backbone’, we cover a range of emerging (‘second-generation’) therapies incorporating other immunotherapies or non-immune based strategies in synergistic combination. These include targeted therapies such as tyrosine kinase inhibitors, co-stimulatory mAbs, bifunctional agents, epigenetic modulators (such as inhibitors of histone deacetylases or DNA methyltransferase), vaccines, adoptive-T-cell therapy, nanoparticles, oncolytic viruses, and even synthetic ‘gene circuits’. A number of novel immunotherapy co-targets in pre-clinical development are also introduced. The latter include metabolic components, exosomes and ion channels. We discuss in some detail of the personalization of immunotherapy essential for ultimate maximization of clinical outcomes. Finally, we outline possible future technical and conceptual developments including realistic in vitro and in vivo models and inputs from physics, engineering and articial intelligence. We conclude that the breadth and quality of immunotherapeutic approaches and the types of cancers that can be treated will increase significantly in the foreseeable future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“Progress in this approach was initially slow, owing to the clinical failure of the CD28 super-agonist mAb TGN1412 that induced “cytokine storms” and life-threatening organ failure in 17% of patients (89).”
BackgroundLag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A., Marabelle, A., Soria, J.-C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,190
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., & Tesei, A. (2016) · Scientific Reports · doi:10.1038/srep19103 · Cited by 1,144
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 2×
“Immune checkpoint inhibitors currently represent the most promising cancer therapeutics where even monotherapies can produce durable responses in 40-50% of patients, persisting long after treatment has ceased (Table 1) (24, 25).”
BackgroundThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785
Exosomes in cancer: small particle, big player
Zhang, X., Yuan, X., Shi, H., Wu, L., Qian, H., & Xu, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0181-x · Cited by 780
Ion Channels in Innate and Adaptive Immunity
Feske, S., Wulff, H., & Skolnik, E. Y. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112212 · Cited by 768
He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 754
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M., Konto, C., & Wolchok, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 714
Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Ionic immune suppression within the tumour microenvironment limits T cell effector function
Eil, R., Vodnala, S. K., Clever, D., Klebanoff, C. A., Sukumar, M., Pan, J. H., Palmer, D. C., Gros, A., Yamamoto, T. N., Patel, S. J., et al. (2016) · Nature · doi:10.1038/nature19364 · Cited by 678
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 651
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 611
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
PD-L1 expression and prognostic impact in glioblastoma
Nduom, E. K., Wei, J., Yaghi, N. K., Huang, N., Kong, L.-Y., Gabrusiewicz, K., Ling, X., Zhou, S., Ivan, C., Chen, J. Q., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov172 · Cited by 596
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Tumorigenesis: it takes a village
Tabassum, D. P., & Polyak, K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3971 · Cited by 564
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
O'Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 514
Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis
Fraser, S. P., Diss, J. K. J., Chioni, A.-M., Mycielska, M. E., Pan, H., Yamaci, R. F., Pani, F., Siwy, Z., Krasowska, M., Grzywna, Z., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0327 · Cited by 481
Self-citationBig opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09538 · Cited by 458
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Klingemann, H., Boissel, L., & Toneguzzo, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00091 · Cited by 414
Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406
Soares, K. C., Rucki, A. A., Wu, A. A., Olino, K., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E., Lutz, E., Liu, L., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 398
The role of the ALK receptor in cancer biology
Hallberg, B., & Palmer, R. H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw301 · Cited by 377
Combination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 374
Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R., Mathew, R. K., Fuller, M. J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7577 · Cited by 373
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
Flint, T. R., Janowitz, T., Connell, C. M., Roberts, E. W., Denton, A. E., Coll, A. P., Jodrell, D. I., & Fearon, D. T. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.010 · Cited by 367
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
A Breakthrough: Macrophage-Directed Cancer Immunotherapy
Mills, C. D., Lenz, L. L., & Harris, R. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1737 · Cited by 356
Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2017) · Nature Communications · doi:10.1038/ncomms14754 · Cited by 350
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A. G., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 336
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Seo, A. N., Lee, H. J., Kim, E. J., Kim, H. J., Jang, M. H., Lee, H. E., Kim, Y. J., Kim, J. H., & Park, S. Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.634 · Cited by 317
Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
Mok, S., Koya, R. C., Tsui, C., Xu, J., Robert, L., Wu, L., Graeber, T. G., West, B. L., Bollag, G., & Ribas, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1816 · Cited by 309
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Anderson, A. C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0039 · Cited by 305
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 305
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer
Grinberg-Bleyer, Y., Oh, H., Desrichard, A., Bhatt, D. M., Caron, R., Chan, T. A., Schmid, R. M., Klein, U., Hayden, M. S., & Ghosh, S. (2017) · Cell · doi:10.1016/j.cell.2017.08.004 · Cited by 297
Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 293
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Cancer as a channelopathy: ion channels and pumps in tumor development and progression
Litan, A., & Langhans, S. A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00086 · Cited by 276
Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis
Kishore, M., Cheung, K. C. P., Fu, H., Bonacina, F., Wang, G., Coe, D., Ward, E. J., Colamatteo, A., Jangani, M., Baragetti, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.017 · Cited by 276
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Converting Cold into Hot Tumors by Combining Immunotherapies
Haanen, J. B. A. G. (2017) · Cell · doi:10.1016/j.cell.2017.08.031 · Cited by 264
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Dempke, W. C. M., Fenchel, K., Uciechowski, P., & Dale, S. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.001 · Cited by 257
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Bartkowiak, T., & Curran, M. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00117 · Cited by 256
Circulating Tumor DNA as Biomarkers for Cancer Detection
Han, X., Wang, J., & Sun, Y. (2017) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.12.004 · Cited by 245
Long, G. V., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30428-x · Cited by 245
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
Lesterhuis, W. J., Bosco, A., Millward, M. J., Small, M., Nowak, A. K., & Lake, R. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.233 · Cited by 243
Hallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 238
Tolcher, A. W., Sznol, M., Hu-Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Di Gravio, D., Huang, B., Gambhire, D., Chen, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1243 · Cited by 236
Pollizzi, K. N., Sun, I.-H., Patel, C. H., Lo, Y.-C., Oh, M.-H., Waickman, A. T., Tam, A. J., Blosser, R. L., Wen, J., Delgoffe, G. M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3438 · Cited by 231
Zika virus has oncolytic activity against glioblastoma stem cells
Zhu, Z., Gorman, M. J., McKenzie, L. D., Chai, J. N., Hubert, C. G., Prager, B. C., Fernandez, E., Richner, J. M., Zhang, R., Shan, C., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171093 · Cited by 230
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
van Baren, N., & Van den Eynde, B. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 228
Adoptive T Cell Immunotherapy For Cancer
Perica, K., Varela, J. C., Oelke, M., & Schneck, J. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10179 · Cited by 224
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M. N., Whitelaw, B. C., Palomar, M. T. P., Wu, Y., & Carroll, P. V. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 220
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
Wilson, M. K., Karakasis, K., & Oza, A. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70375-4 · Cited by 219
Epigenetic treatment of solid tumours: a review of clinical trials
Nervi, C., De Marinis, E., & Codacci-Pisanelli, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0157-2 · Cited by 213
Noncanonical Roles of Voltage-Gated Sodium Channels
Black, J. A., & Waxman, S. G. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.012 · Cited by 209
El Osta, B., Hu, F., Sadek, R., Chintalapally, R., & Tang, S.-C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 209
Herranz, D., Ambesi-Impiombato, A., Sudderth, J., Sánchez-Martín, M., Belver, L., Tosello, V., Xu, L., Wendorff, A. A., Castillo, M., Haydu, J. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3955 · Cited by 208
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Hu-Lieskovan, S., Robert, L., Homet Moreno, B., & Ribas, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.1377 · Cited by 199
Baginska, J., Viry, E., Paggetti, J., Medves, S., Berchem, G., Moussay, E., & Janji, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00490 · Cited by 198
Wang, L., Le Mercier, I., Putra, J., Chen, W., Liu, J., Schenk, A. D., Nowak, E. C., Suriawinata, A. A., Li, J., & Noelle, R. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407447111 · Cited by 195
Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 188
CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation
Chikuma, S. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_61 · Cited by 187
T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
Houot, R., Schultz, L. M., Marabelle, A., & Kohrt, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0190 · Cited by 185
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
Moffett, H. F., Coon, M. E., Radtke, S., Stephan, S. B., McKnight, L., Lambert, A., Stoddard, B. L., Kiem, H. P., & Stephan, M. T. (2017) · Nature Communications · doi:10.1038/s41467-017-00505-8 · Cited by 183
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
Durham, N. M., Nirschl, C. J., Jackson, C. M., Elias, J., Kochel, C. M., Anders, R. A., & Drake, C. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109080 · Cited by 178
MacFarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al-Saleem, T., & Campbell, K. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0133 · Cited by 177
Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy
Nissim, L., Wu, M.-R., Pery, E., Binder-Nissim, A., Suzuki, H. I., Stupp, D., Wehrspaun, C., Tabach, Y., Sharp, P. A., & Lu, T. K. (2017) · Cell · doi:10.1016/j.cell.2017.09.049 · Cited by 175
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
Tinoco, R., Carrette, F., Barraza, M. L., Otero, D. C., Magaña, J., Bosenberg, M. W., Swain, S. L., & Bradley, L. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.015 · Cited by 173
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 173
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Morrissey, K., Yuraszeck, T., Li, C., Zhang, Y., & Kasichayanula, S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12391 · Cited by 171
PD-1 blockade enhances the vaccination-induced immune response in glioma
Antonios, J. P., Soto, H., Everson, R. G., Orpilla, J., Moughon, D., Shin, N., Sedighim, S., Yong, W. H., Li, G., Cloughesy, T. F., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87059 · Cited by 170
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0195-4 · Cited by 169
Targeting minimal residual disease: a path to cure?
Luskin, M. R., Murakami, M. A., Manalis, S. R., & Weinstock, D. M. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.125 · Cited by 168
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 166
A Genetic Porcine Model of Cancer
Schook, L. B., Collares, T. V., Hu, W., Liang, Y., Rodrigues, F. M., Rund, L. A., Schachtschneider, K. M., Seixas, F. K., Singh, K., Wells, K. D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128864 · Cited by 161
Danilova, L., Wang, H., Sunshine, J., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 161
Patient-derived xenografts: a relevant preclinical model for drug development
Pompili, L., Porru, M., Caruso, C., Biroccio, A., & Leonetti, C. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0462-4 · Cited by 161
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
Hasmim, M., Messai, Y., Ziani, L., Thiery, J., Bouhris, J.-H., Noman, M. Z., & Chouaïb, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00482 · Cited by 160
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Mazzone, R., Zwergel, C., Mai, A., & Valente, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0358-y · Cited by 160
Systems biology approaches for advancing the discovery of effective drug combinations
Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 159
Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
Sapkota, B., Hill, C. E., & Pollack, B. P. (2013) · OncoImmunology · doi:10.4161/onci.22890 · Cited by 158
Nivolumab in melanoma: latest evidence and clinical potential
Johnson, D. B., Peng, C., & Sosman, J. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014567469 · Cited by 158
Romagnoli, G. G., Zelante, B. B., Toniolo, P. A., Migliori, I. K., & Barbuto, J. A. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00692 · Cited by 152
Ali, O. A., Lewin, S. A., Dranoff, G., & Mooney, D. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0126 · Cited by 151
Baptista‐Hon, D. T., Robertson, F. M., Robertson, G. B., Owen, S. J., Rogers, G. W., Lydon, E., Lee, N. H., & Hales, T. G. (2014) · British Journal of Anaesthesia · doi:10.1093/bja/aeu104 · Cited by 145
Liu, Y., Maccarini, P. F., Palmer, G. M., Etienne, W., Zhao, Y., Lee, C.-T., Ma, X., Inman, B. A., & Vo‐Dinh, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-09116-1 · Cited by 144
Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity
Hargadon, K. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00192 · Cited by 140
Engineering opportunities in cancer immunotherapy
Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 135
Bose, T., Cieślar‐Pobuda, A., & Wiecheć, E. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.23 · Cited by 131
Designer exosomes as next-generation cancer immunotherapy
Bell, B. M., Kirk, I. D., Hiltbrunner, S., Gabrielsson, S., & Bultema, J. J. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.09.011 · Cited by 129
Gökbuget, N., Kelsh, M. A., Chia, V., Advani, A. S., Bassan, R., Dombret, H., Doubek, M., Fielding, A. K., Giebel, S., Haddad, V., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.84 · Cited by 127
A global transcriptional network connecting noncoding mutations to changes in tumor gene expression
Zhang, W., Bojorquez-Gomez, A., Velez, D. O., Xu, G., Sanchez, K. S., Shen, J. P., Chen, K., Licon, K., Melton, C. A., Olson, K. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0091-2 · Cited by 127
Macrophage-Dependent Cytoplasmic Transfer during Melanoma Invasion In Vivo
Roh‐Johnson, M., Shah, A. N., Stonick, J. A., Poudel, K. R., Kargl, J., Yang, G. H. Y., Martino, J. S. D., Hernandez, R. E., Gast, C. E., Zarour, L. R., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.11.003 · Cited by 126
Carlsten, M., Levy, E. R., Karambelkar, A. D., Li, L., Reger, R. N., Berg, M., Peshwa, M. V., & Childs, R. W. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00105 · Cited by 123
Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
Pantziarka, P., Sukhatme, V. V., Bouche, G., Melhuis, L., & Sukhatme, V. P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.610 · Cited by 119
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
Marchini, A., Scott, E. M., & Rommelaere, J. (2016) · Viruses · doi:10.3390/v8010009 · Cited by 118
A voltage-gated sodium channel is essential for the positive selection of CD4+ T cells
Lo, W., Donermeyer, D. L., & Allen, P. M. (2012) · Nature Immunology · doi:10.1038/ni.2379 · Cited by 116
Quantum computers ready to leap out of the lab in 2017
Castelvecchi, D. (2017) · Nature · doi:10.1038/541009a · Cited by 116
The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities
Silver, D. J., Sinyuk, M., Vogelbaum, M. A., Ahluwalia, M. S., & Lathia, J. D. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov157 · Cited by 114
Harnessing the exosome-induced immune response for cancer immunotherapy
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.003 · Cited by 111
Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity
Tan, P., He, L., Han, G., & Zhou, Y. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.09.002 · Cited by 108
A novel polyclonal antibody specific for the Nav1.5 voltage-gated Na+ channel ‘neonatal’ splice form
Chioni, A., Fraser, S. P., Pani, F., Foran, P., Wilkin, G. P., Diss, J. K. J., & Djamgoz, M. B. A. (2005) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2005.03.010 · Cited by 101
Self-citationImmunotherapy: The Path to Win the War on Cancer?
Topalian, S. L., Wolchok, J. D., Chan, T. A.-T., Mellman, I., Palucka, K., Banchereau, J., Rosenberg, S. A., & Wittrup, K. D. (2015) · Cell · doi:10.1016/j.cell.2015.03.045 · Cited by 99
Recent advances in the field of anti-cancer immunotherapy
Neves, H., & Kwok, H. F. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.04.001 · Cited by 97
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D. E., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 96
Cancer vaccines: Looking to the future
Yaddanapudi, K., Mitchell, R. A., & Eaton, J. W. (2013) · OncoImmunology · doi:10.4161/onci.23403 · Cited by 93
Shindo, Y., Yoshimura, K., Kuramasu, A., Watanabe, Y., Ito, H., Kondo, T., Oga, A., Ito, H., Yoshino, S., Hazama, S., et al. (2015) · PubMed · Cited by 90
Berdeja, J. G., Lin, Y., Raje, N. S., Munshi, N. C., Siegel, D. S. D., Liedtke, M., Jagannath, S., Maus, M. V., Turka, A., Lam, L. P., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.740.740 · Cited by 86
Vasaturo, A., Blasio, S. D., Peeters, D. G. A., de Koning, C. C. H., de Vries, I. J. M., Figdor, C. G., & Hato, S. V. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00417 · Cited by 85
Chowdhury, S., McDermott, D. F., Voss, M. H., Hawkins, R. E., Aimone, P., Voi, M., Isabelle, N., Wu, Y.-L. L. C., & Infante, J. R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4506 · Cited by 84
Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery
Tănase, C., Codrici, E., Popescu, I. D., Mihai, S., Enciu, A., Necula, L. G., Preda, A., Ismail, G., & Albulescu, R. (2017) · Oncotarget · doi:10.18632/oncotarget.14501 · Cited by 81
Sharabi, A. B., Tran, P. T., Lim, M. K., Drake, C. G., & DeWeese, T. L. (2015) · PubMed · Cited by 77
Gangadhar, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Luke, J. J., Balmanoukian, A. S., Kaufman, D. R., Zhao, Y., Maleski, J. E., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o7 · Cited by 77
Learning from PD-1 Resistance: New Combination Strategies
Bu, X., Mahoney, K. M., & Freeman, G. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.008 · Cited by 74
Obesity and Cancer Metabolism: A Perspective on Interacting Tumor–Intrinsic and Extrinsic Factors
Doerstling, S. S., O’Flanagan, C. H., & Hursting, S. D. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00216 · Cited by 73
Naka, K., Jomen, Y., Ishihara, K., Kim, J., Ishimoto, T., Bae, E., Mohney, R. P., Stirdivant, S. M., Oshima, H., Oshima, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9039 · Cited by 68
Phan-Lai, V., Florczyk, S. J., Kievit, F. M., Wang, K., Gad, E. A., Disis, M. L., & Zhang, M. (2013) · Biomacromolecules · doi:10.1021/bm301928u · Cited by 64
Ion channels and anti-cancer immunity
Panyi, G., Beeton, C., & Felipe, A. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0106 · Cited by 64
Take two: Combining immunotherapy with epigenetic drugs to tackle cancer
Weintraub, K. (2016) · Nature Medicine · doi:10.1038/nm0116-8 · Cited by 63
調節性T細胞移動はグルコキナーゼ仲介される解糖に依存している【Powered by NICT】
Madhav, K., Kenneth, C. P. C., Hongmei, F., et al. (2017) · Immunity · Cited by 62
Wang, W., Wu, L., Zhang, J., Wu, H., Han, E.-K., & Guo, Q. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.180 · Cited by 61
Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification
Widjaja, C. E., Olvera, J. G., Metz, P. J., Phan, A. T., Savas, J. N., de Bruin, G., Leestemaker, Y., Berkers, C. R., de Jong, A., Florea, B. I., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90895 · Cited by 60
Chimote, A. A., Hajdú, P., Sfyris, A. M., Gleich, B. N., Wise-Draper, T. M., Casper, K. A., & Conforti, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2372 · Cited by 59
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
Kärpänen, T., & Olweus, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01718 · Cited by 59
Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective
Missiaen, R., Morales-Rodriguez, F., Eelen, G., & Carmeliet, P. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.001 · Cited by 58
Koshy, S., Wu, D., Hu, X., Tajhya, R. B., Huq, R., Khan, F. S., Pennington, M. W., Wulff, H., Yotnda, P., & Beeton, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076740 · Cited by 58
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
Immunotherapy at Large: The road to personalized cancer vaccines
Vonderheide, R. H., & Nathanson, K. L. (2013) · Nature Medicine · doi:10.1038/nm.3317 · Cited by 54
Exosomes for Immunoregulation and Therapeutic Intervention in Cancer
Zhang, X., Pei, Z., Chen, J., Ji, C., Xu, J., Zhang, X., & Wang, J. (2016) · Journal of Cancer · doi:10.7150/jca.14866 · Cited by 54
Cottu, P. H., D’Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P., Duhoux, F. P., Lévy, C., Mouret-Reynier, M.-A., Dalenc, F., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440 · Cited by 50
The dark side of PD-1 receptor inhibition
Ludin, A., & Zon, L. I. (2017) · Nature · doi:10.1038/nature24759 · Cited by 50
Liu, Y., Zhao, L., Ma, W., Cao, X., Chen, H., Feng, D., Liang, J., Yin, K., & Jiang, X. (2015) · Journal of Cancer · doi:10.7150/jca.11913 · Cited by 48
Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy
Park, J., Thomas, S., & Münster, P. N. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 47
Jing, W., Gershan, J. A., & Johnson, B. D. (2009) · Blood · doi:10.1182/blood-2008-11-190827 · Cited by 47
Neonatal Nav1.5 protein expression in normal adult human tissues and breast cancer
Yamaci, R. F., Fraser, S. P., Battaloğlu, E., Kaya, H., Erguler, K., Foster, C. S., & Djamgoz, M. B. A. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.06.003 · Cited by 46
Self-citation
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
The importance of exosomal PDL1 in tumour immune evasion
Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
Metadata
- Authors
- Marshall, H. T., & Djamgoz, M. B. A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-08-23
- Volume
- 8
- Pages
- 315-315
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2888555926
- Cited by
- 301
- References
- 226
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.